Clinical research
Sinopharm, a Chinese biopharmaceutical company controlled by the state, announced that its COVID-19 vaccine candidate had an efficacy rate of 79% based on interim analysis of Phase III trials.
Fabry disease is a rare, X-linked inherited disease that results from abnormal deposits of a fatty substance in blood vessels.
Shares of Aprea Therapeutics plunged more than 77% in morning trading after the company announced its late-stage cancer combination treatment failed to meet its primary endpoint of complete remission rate.
Even with the holidays among us, there were a number of clinical trial announcements. Here’s a look.
In October, the FDA placed a clinical hold on the company’s Huntington’s disease gene therapy before that asset could make its way into the clinic.
As a result, the company has decided to unblind the treatment assignments of patients in the trial.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 29, 2020.
Rhythm Pharmaceuticals announced on Tuesday that its hunger and severe obesity drug, setmelanotide, significantly reduced weight and hunger scores in people with Bardet-Biedl syndrome and Alström syndrome.
An investigational asthma treatment, tezepelumab, under development by Amgen and AstraZeneca failed to reduce asthma patients’ dependence on corticosteroids.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 22, 2020.
PRESS RELEASES